Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273931 | 1.00 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL12980340 | 1.00 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL15705128 | 0.87 | KCNN4 (0.35) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL17118662 | 0.82 | KCNN4 (0.34) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL17749269 | 0.79 | KCNN4 (0.41) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL12980676 | 0.78 | KCNN4 (0.36) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL12980706 | 0.78 | KCNN4 (0.36) | KCNN4KCNE1KCNQ1KIF11 | |
| SCHEMBL13835815 | 0.78 | ADRB2 (0.33) | — | |
| SCHEMBL15602054 | 0.76 | KCNN4 (0.42) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL15536032 | 0.76 | KCNN4 (0.42) | HDAC3HDAC1HDAC2HDAC6KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | HDAC3 2630/4885HDAC1 597/4885HDAC2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.